Skip to main content
logo
Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
37.72
-1.34 (-3.43%)
At close: Mar 3, 2026, 4:00 PM EST
38.20
+0.48 (1.27%)
After-hours: Mar 3, 2026, 7:18 PM EST

Soleno Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
190.41----
Cost of Revenue
2.7----
Gross Profit
187.71----
Selling, General & Admin
132.13105.8613.489.8410.81
Research & Development
40.6378.5725.1915.2721.45
Operating Expenses
172.76184.4338.6725.1132.26
Operating Income
14.95-184.43-38.67-25.11-32.26
Interest Expense
-5.48-0.23---
Interest & Investment Income
16.9512.052.580.30.11
Other Non Operating Income (Expenses)
---0.180.030.51
EBT Excluding Unusual Items
26.43-172.61-36.27-24.78-31.64
Other Unusual Items
-5.54-3.24-2.710.710.73
Pretax Income
20.89-175.85-38.99-24.07-30.91
Earnings From Continuing Operations
20.89-175.85-38.99-24.07-30.91
Net Income
20.89-175.85-38.99-24.07-30.91
Preferred Dividends & Other Adjustments
0.42----
Net Income to Common
20.48-175.85-38.99-24.07-30.91
Shares Outstanding (Basic)
51401685
Shares Outstanding (Diluted)
52401685
Shares Change (YoY)
30.39%143.61%96.40%57.90%27.39%
EPS (Basic)
0.40-4.38-2.36-2.87-5.81
EPS (Diluted)
0.39-4.38-2.36-2.87-5.81
Free Cash Flow
46.73-69.31-24.94-20.79-27.79
Free Cash Flow Per Share
0.89-1.73-1.51-2.48-5.23
Gross Margin
98.58%----
Operating Margin
7.85%----
Profit Margin
10.75%----
Free Cash Flow Margin
24.54%----
EBITDA
16.97-182.44-36.71-23.15-30.3
EBITDA Margin
8.91%----
D&A For EBITDA
2.021.991.961.961.96
EBIT
14.95-184.43-38.67-25.11-32.26
EBIT Margin
7.85%----
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q